CCXI ChemoCentryx Inc.

16.9
-0.18  -1%
Previous Close 17.08
Open 17.08
52 Week Low 9.53
52 Week High 70.29
Market Cap $1,181,369,235
Shares 69,903,505
Float 47,274,691
Enterprise Value $911,110,762
Volume 758,535
Av. Daily Volume 1,393,288
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Avacopan (CCX168) - (ADVOCATE)
Associated vasculitis (AAV)
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Avacopan (CCX168)
Hidradenitis Suppurativa (HS)
Phase 3
Phase 3
Phase 2b data released October 28, 2020. Primary endpoint across Hurley Stages 2 and 3 not met. Phase 3 trial planned in Stage 3 patients.
CCX559
Cancer
Phase 1
Phase 1
Phase 1 trial initiated 2Q 2021.
Avacopan (CCX168)
Lupus nephritis
Phase 1
Phase 1
Phase 1 trial to be initiated 1H 2022.
Avacopan (CCX168) - (ACCOLADE)
C3 glomerulopathy (C3G)
Phase 2
Phase 2
Phase 2 trial did not meet primary endpoint - December 21, 2020.
CCX140 - LUMINA-1
Focal Segmental Glomerulosclerosis
Phase 2
Phase 2
Phase 2 trial did not meet primary endpoint - May 18, 2020.

Latest News

  1. SAN CARLOS, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:

    • 2021 Virtual Wells Fargo Healthcare Conference
      Fireside Chat Thursday, September 9 at 4:40 p.m. Eastern Time
    • H.C. Wainwright 23rd Annual Global Investment Conference
      On-demand presentation available beginning Monday, September 13 at 6:00 a.m. Eastern Time

    Live audio webcasts of the Wells Fargo fireside chat, as well as the on-demand H.C. Wainwright presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of both the Wells Fargo and H.C. Wainwright presentations…

    SAN CARLOS, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:

    • 2021 Virtual Wells Fargo Healthcare Conference

      Fireside Chat Thursday, September 9 at 4:40 p.m. Eastern Time
    • H.C. Wainwright 23rd Annual Global Investment Conference

      On-demand presentation available beginning Monday, September 13 at 6:00 a.m. Eastern Time

    Live audio webcasts of the Wells Fargo fireside chat, as well as the on-demand H.C. Wainwright presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of both the Wells Fargo and H.C. Wainwright presentations will be available on the Company's website for two weeks following the respective presentation dates.

    About ChemoCentryx

    ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

    ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

    Contacts:

    Susan M. Kanaya                                        

    Executive Vice President,                                         

    Chief Financial and Administrative Officer

    investor@chemocentryx.com                               

    Media:

    Stephanie Tomei

    408.234.1279

    media@chemocentryx.com

    Investors:

    Lee Roth, Burns McClellan

    212.213.0006

    lroth@burnsmc.com



    Primary Logo

    View Full Article Hide Full Article
  2. -- Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021--

    -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis also under review by the European Medicines Agency and the Japan Pharmaceuticals and Medical Devices Agency --

    -- Clinical development launched of potential next generation checkpoint inhibitor CCX559, featured in abstract at Annual Meeting of American Association for Cancer Research --

    -- $402.6 million in cash and investments at June 30, 2021 --

    -- Conference call today at 5:00 p.m. Eastern Time --

    SAN CARLOS, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced financial…

    -- Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021--

    -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis also under review by the European Medicines Agency and the Japan Pharmaceuticals and Medical Devices Agency --

    -- Clinical development launched of potential next generation checkpoint inhibitor CCX559, featured in abstract at Annual Meeting of American Association for Cancer Research --

    -- $402.6 million in cash and investments at June 30, 2021 --

    -- Conference call today at 5:00 p.m. Eastern Time --

    SAN CARLOS, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced financial results for the second quarter ended June 30, 2021 and provided an overview of recent corporate highlights.

    "We appreciate the recent opportunity to provide the U.S. FDA with supplementary data and analyses to our NDA, which the Agency deemed to be a major amendment," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We are looking forward to decisions later this year on regulatory submissions for avacopan in ANCA-associated vasculitis in the U.S. and abroad. Meanwhile, we are further developing our pipeline, as evidenced by the launch of a Phase I study with our novel orally-administered immune checkpoint inhibitor CCX559, which we hope will be part of a new era of precise cancer treatment. Further clinical work in other high need areas, such as the initiation of a Phase III trial of avacopan in patients with severe Hidradenitis Suppurativa, constitute important next steps in building the CCXI pipeline to benefit patients most in need."

    Key Second Quarter 2021 Highlights and Recent Developments

    • In July the Company announced the filing of additional information to its NDA submission, which the FDA deemed to be a major amendment. The PDUFA review period for avacopan in the treatment of ANCA-associated vasculitis was extended, with a new PDUFA goal date of October 7, 2021. The Company's filing followed the May 6 meeting of the FDA's Arthritis Advisory Committee.
    • In Q2, the Company initiated Phase I clinical development of CCX559, a novel, orally-administered, PD-1/PD-L1 checkpoint inhibitor. CCX559 was featured in an abstract at the April 2021 Annual Meeting of the American Association for Cancer Research (AACR). As a next generation therapy, small molecule inhibitors may have advantageous properties compared to approved monoclonal antibodies, such as better penetration into solid tumors, reduced immunogenicity, lack of Fc-mediated side effects, and the convenience of oral administration.
    • The Company plans to meet with the FDA to discuss the Phase III development of avacopan in patients with Hurley Stage 3 (severe) Hidradenitis Suppurativa (HS) with the goal of initiating a Phase III clinical trial in those patients. In the Phase II AURORA trial, avacopan demonstrated a statistically significant higher response than placebo in a pre-specified subgroup of Hurley Stage 3 patients, which will further guide clinical development.
    • The Company plans to initiate clinical development of avacopan in patients with lupus nephritis in the first half of 2022.
    • The Company also plans to schedule a meeting later this year with the FDA to discuss evidence of clinical benefit from the ACCOLADE trial of avacopan in the very rare disorder C3 Glomerulopathy (C3G). There are no FDA approved therapies for this rare disorder. In the ACCOLADE trial, avacopan demonstrated statistically significant improvement in renal function as measured by pre-specified secondary endpoints of eGFR and also improvement in the pre-specified endpoint of C3G Histology Index (HI) Disease Chronicity score, compared to placebo over 26 weeks of blinded treatment, while not attaining a statistically significant improvement in the primary endpoint of the C3G HI Disease Activity Score. Avacopan was well tolerated in C3G patients.
    • The Company ended Q2 with cash, cash equivalents and investments of $402.6 million at June 30, 2021.

    Second Quarter 2021 Financial Results

    Revenue was $1.8 million for the second quarter of 2021, compared to $49.4 million for the same period in 2020. The decrease in revenue from 2020 to 2021 was principally attributable to the acceleration of revenue recognition in 2020 associated with the decision to discontinue development of CCX140 in Focal Segmental Glomerulosclerosis (FSGS).

    Research and development expenses were $20.9 million for the second quarter of 2021, compared to $18.8 million for the same period in 2020. The increase from 2020 to 2021 was primarily attributable to the manufacture of commercial drug supply in anticipation of the launch of avacopan for the treatment of ANCA vasculitis and higher research and drug discovery expenses, including those associated with the development of CCX559, the Company's orally-available small molecule checkpoint (PD-1/PD-L1) inhibitor.  These increases were partially offset by lower Phase II related expenses due to the completion of the avacopan AURORA Phase IIb clinical trial in patients with HS and the discontinuation of further clinical development of CCX140 in FSGS in 2020.

    General and administrative expenses were $19.7 million for the second quarter of 2021, compared to $10.3 million for the same period in 2020. The increase from 2020 to 2021 was primarily due to higher employee-related expenses, including those associated with the Company's commercialization planning efforts, and higher professional fees.  

    Net loss for the second quarter of 2021 was $39.2 million, compared to net income of $20.3 million for the same period in 2020.

    Total shares outstanding at June 30, 2021 were approximately 69.9 million shares.

    Cash, cash equivalents and investments totaled $402.6 million at June 30, 2021.

    Conference Call and Webcast

    The Company will host a conference call and webcast today, August 9, 2021 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 2164528. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

    About ChemoCentryx

    ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

    ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

    Forward-Looking Statements

    ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the timing of the anticipated PDUFA date for the avacopan NDA for the treatment of ANCA-associated vasculitis, the achievement of anticipated goals and milestones, whether avacopan will be approved by the FDA for the treatment of ANCA-associated vasculitis, whether avacopan will be shown to be effective in the treatment of Hurley Stage 3 (severe) HS and C3G and whether the Company's drug candidates, including CCX559, will be shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC on March 1, 2021 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Contacts:

    Susan M. Kanaya

    Executive Vice President,

    Chief Financial and Administrative Officer

    investor@chemocentryx.com 

    Media:

    Stephanie Tomei

    408.234.1279

    media@chemocentryx.com

    Investors:

    Burns McClellan

    Lee Roth

    212.213.0006

    lroth@burnsmc.com

    ChemoCentryx, Inc.          
    Condensed Consolidated Financial Statements Data         
    (in thousands, except per share data)      
       Three Months Ended Six Months Ended 
       June 30, June 30, 
        2021   2020   2021   2020  
         
       (unaudited) 
    Condensed Consolidated Statements of Operations Data:         
    Revenue:          
    Collaboration and license revenue from related party $1,699  $49,283  $11,922  $55,138  
    Grant revenue   114   157   244   310  
    Total revenue  1,813   49,440   12,166   55,448  
               
    Operating expenses:         
    Research and development  20,853   18,762   44,271   38,073  
    General and administrative  19,698   10,292   35,960   19,112  
    Total operating expenses  40,551   29,054   80,231   57,185  
    Income (loss) from operations  (38,738)  20,386   (68,065)  (1,737) 
    Total other income (expense), net  (471)  (119)  (855)  317  
    Net income (loss)  $(39,209) $20,267  $(68,920) $(1,420) 
               
    Net income (loss) per common share:         
    Basic  $(0.56) $0.32  $(0.99) $(0.02) 
    Diluted  $(0.56) $0.29  $(0.99) $(0.02) 
               
    Shares used to compute net income (loss) per common share:         
    Basic   69,788   63,282   69,698   62,289  
    Diluted   69,788   69,416   69,698   62,289  
               
           June 30, December 31,
    Condensed Consolidated Balance Sheets Data:      2021   2020  
    Cash, cash equivalents and investments     (unaudited)   
    Working capital          
    Total assets      $402,632  $460,370  
    Long-term debt, net       261,754   390,012  
    Accumulated deficit       467,672   518,899  
    Total stockholders' equity      24,550   24,401  
            (554,262)  (485,342) 
            330,270   385,613  
                       

     



    Primary Logo

    View Full Article Hide Full Article
  3. SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m. ET.

    A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.

    About ChemoCentryx
    ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant…

    SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m. ET.

    A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.

    About ChemoCentryx

    ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

    ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

    Contacts:

    Susan M. Kanaya

    Executive Vice President,

    Chief Financial and Administrative Officer

    investor@chemocentryx.com

    Media:

    Stephanie Tomei

    408.234.1279

    media@chemocentryx.com

    Investors:

    Lee Roth, Burns McClellan

    212.213.0006

    lroth@burnsmc.com



    Primary Logo

    View Full Article Hide Full Article
  4. MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2021 financial results will be released after market close on Monday, August 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2021 to discuss these results and to answer questions.

    To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 2164528. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen…

    MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2021 financial results will be released after market close on Monday, August 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2021 to discuss these results and to answer questions.

    To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 2164528. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

    About ChemoCentryx

    ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

    ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

    Contacts:

    Susan M. Kanaya

    Executive Vice President,

    Chief Financial and Administrative Officer

    investor@chemocentryx.com

    Media:

    Stephanie Tomei

    408.234.1279

    media@chemocentryx.com

    Investors:

    Lee Roth, Burns McClellan

    212.213.0006

    lroth@burnsmc.com



    Primary Logo

    View Full Article Hide Full Article
  5. SAN CARLOS, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) for avacopan for the treatment of Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis, addressing points raised during the FDA Advisory Committee meeting on May 6, 2021. The FDA has indicated that the filing constitutes a major amendment to the NDA and will result in the setting of a new PDUFA goal date of October 7, 2021. The NDA is primarily based on data from the Phase III ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitis. On May 6, the FDA's Arthritis Advisory…

    SAN CARLOS, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) for avacopan for the treatment of Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis, addressing points raised during the FDA Advisory Committee meeting on May 6, 2021. The FDA has indicated that the filing constitutes a major amendment to the NDA and will result in the setting of a new PDUFA goal date of October 7, 2021. The NDA is primarily based on data from the Phase III ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitis. On May 6, the FDA's Arthritis Advisory Committee voted 9-9 on whether the efficacy data support approval of avacopan, 10-8 that the safety profile of avacopan is adequate to support approval, and 10-8 that the benefit-risk profile is adequate to support approval of avacopan at the proposed dose of 30 mg twice daily.

    "We appreciate the opportunity to put additional data and information before the Agency, information which we believe addresses many of the issues raised at the Advisory Committee meeting," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We look forward to continuing discussions with the Agency."

    The Marketing Authorization Application (MAA) for avacopan in the treatment of ANCA-associated vasculitis was validated by the European Medicines Agency (EMA) in November 2020, and the Japanese New Drug Application was accepted for review by the Japanese Pharmaceuticals and Medical Device Agency in February 2021.

    About ADVOCATE and ANCA-Associated Vasculitis

    The ADVOCATE trial of avacopan was a global, randomized, double-blind, active-controlled, double-dummy Phase III trial of 331 patients with ANCA-associated vasculitis in 20 countries. Eligible study subjects were randomized to receive avacopan plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate) or study-supplied oral prednisone plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate). Subjects in both treatment groups could also receive non-protocol glucocorticoids if needed.

    ANCA-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated. Currently, treatment for ANCA-associated vasculitis consists of courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with the administration of daily glucocorticoids (steroids) for prolonged periods of time, which can be associated with significant clinical risk including death from infection.

    About Avacopan

    Avacopan is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis and other complement-driven autoimmune and inflammatory diseases. By precisely blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA-associated vasculitis. Current therapies for ANCA-associated vasculitis and other related illnesses typically include broad immunosuppression with daily doses of glucocorticoids (steroids) such as prednisone or methylprednisone, which can cause significant illness and even death. Avacopan's selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally.

    ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted avacopan orphan drug designation for ANCA-associated vasculitis and C3G. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G.

    ChemoCentryx is responsible for the discovery and development of avacopan and owns and retains the commercial rights to the drug in the United States. ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan in markets outside of the U.S.

    About ChemoCentryx

    ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

    Forward-Looking Statements

    ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the timing of anticipated PDUFA date for the avacopan NDA for the treatment of ANCA-associated vasculitis, the achievement of anticipated goals and milestones, whether avacopan will be approved by the FDA for the treatment of ANCA-associated vasculitis, and whether the Company's drug candidates will be shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC on March 1, 2021 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Contacts:

    Susan M. Kanaya

    Executive Vice President,

    Chief Financial and Administrative Officer

    investor@chemocentryx.com

    Media:

    Stephanie Tomei

    408.234.1279

    media@chemocentryx.com

    Investors:

    Burns McClellan, Inc.

    Lee Roth

    212.213.0006

    lroth@burnsmc.com



    Primary Logo

    View Full Article Hide Full Article
View All ChemoCentryx Inc. News